Every 8-K that Turn Therapeutics Inc. (TTRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.
Turn Therapeutics Inc. (TTRX) reported that it will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum under a Regulation FD disclosure.
On September 23, 2026, Chief Executive Officer Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., are scheduled to present an update on the atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy and emerging findings in distinct patient populations. The presentation will be available via live webcast and replay for approximately six months on the company’s investor relations website.
Turn Therapeutics Inc. (TTRX) filed a report describing the appointment of Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. He brings over four decades of experience in immunology, microbiology, infectious disease, and public health, including academic leadership at the University of Maryland and research service in the U.S. Army Medical Corps.
Dr. Redfield will help guide the scientific and clinical strategy for Turn Therapeutics’ lead candidate GX-03 in atopic dermatitis and onychomycosis, and potential additional indications that involve localized microbial and inflammatory processes. The company remains focused on developing targeted, non-systemic therapies acting directly at the site of disease.
Turn Therapeutics Inc. reported that GEM Yield Bahamas Limited exercised in full a previously issued warrant to acquire common stock using a cashless exercise feature. The warrant, originally issued on October 8, 2025, covered 1,192,207 shares, which represented 4% of Turn Therapeutics’ fully diluted outstanding shares as of that date and carried an exercise price of $5.03 per share.
Because the defined Per Share Market Value exceeded the warrant price, GEM elected the cashless exercise mechanism, and on August 13, 2026 Turn Therapeutics issued 579,664 shares of common stock to GEM. The company states that this unregistered issuance relied on the Section 4(a)(2) exemption under the Securities Act, based on GEM’s status as an accredited investor under Regulation D.
Turn Therapeutics Inc. entered into securities purchase agreements with certain accredited investors, primarily existing series and seed investors, to complete a private equity financing. The company agreed to issue and sell 135,000 shares of common stock at a purchase price of $10.00 per share, resulting in aggregate gross proceeds of $1.35 million.
The transaction was structured as a private placement relying on the registration exemptions under Section 4(a)(2) of the Securities Act of 1933 and Regulation D for transactions not involving a public offering. Turn Therapeutics also granted the investors registration rights for these shares, enabling potential future resale under a registration statement.
Turn Therapeutics reported second-quarter 2026 results and provided clinical updates for lead topical candidate GX-03 in atopic dermatitis. In an interim Phase 2 analysis using final Stage 2 criteria, GX-03 showed treatment separation from vehicle across four efficacy endpoints, including 61.5% vs 8.3% of patients achieving clear or almost clear skin at Week 4 and 46.2% vs 8.3% achieving complete EASI clearance at Week 8. Stage 1 showed a favorable safety profile with no serious adverse events or discontinuations.
Based on these data, Stage 2 enrollment was expanded to approximately 120–135 patients with planned statistical power of at least 99.8% across the four endpoints, with enrollment expected to complete in the fourth quarter of 2026. The company also plans a Phase 2a study of GX-03 in hidradenitis suppurativa with about 60 patients, targeting first patient dosing in the second quarter of 2027.
Financially, Turn reported a Q2 2026 net loss of $5,849,734 and basic and diluted net loss per share of $0.20. Cash and cash equivalents were $10,288,510 as of June 30, 2026, and the company expects its cash to fund operations into the third quarter of 2027.
Turn Therapeutics Inc. presents an updated investor overview centered on GX-03, a first-in-class, non-systemic immunomodulation therapy delivered via its PermaFusion platform to target IL‑36 and related cytokines in inflammatory diseases including moderate to severe atopic dermatitis (AD), onychomycosis and hidradenitis suppurativa.
In an ongoing Phase 2 AD trial (planned N = ~ 120-135), a Stage 1 subgroup with baseline PP‑NRS ≥ 7 (GX‑03 n=13, vehicle n=12) showed week‑4 vIGA‑AD success in 61.5% of GX‑03 patients versus 8.3% on vehicle, and EASI‑75 in 69.2% versus 25.0%. Safety data include over 200,000+ patients previously treated with GX‑03 in other indications with zero reported adverse events, plus Phase 2 Stage 1 results showing only one non‑severe adverse event in each arm.
Planned milestones, subject to successful completion of each phase and capital availability, include a Phase 2 AD topline readout in Q4 2026, Phase 3 initiations in AD and onychomycosis in 2027, and a Phase 2a trial in HS. A financial snapshot shows cash of $11 as of March 31, 2026, cash runway into Q3 2027, current G&A burn of ~$250K per month, total capital raised of ~$29M, and 17 issued patents with coverage through 2040.
Turn Therapeutics provided a detailed update on its adaptive Phase 2 trial of GX-03 for atopic dermatitis, based on a comprehensive interim analysis. GX-03 showed clinically meaningful efficacy across a broader range of disease severity than originally expected, including patients with EASI scores of 1.1–7.0, which are typically considered mild-to-moderate.
In this EASI 1.1–7.0 subgroup, Week 4 vIGA-AD Success was 71.4% for GX-03 versus 33.3% for vehicle, and Week 8 EASI-100 was 35.7% versus 11.1%. A representative enriched subgroup (baseline EASI ≥1.1 and PP-NRS ≥7) also showed strong separation, with Week 4 vIGA-AD Success of 61.5% for GX-03 versus 8.3% for vehicle.
The final Stage 2 design will enroll about 120–135 patients across the full EASI spectrum, stratified by baseline severity and evaluated on four prespecified efficacy endpoints using the FDA-recognized Hochberg multiple testing procedure. No treatment-related serious adverse events or discontinuations have been reported, and GX-03 continues to show a favorable safety and tolerability profile. Turn Therapeutics anticipates completing enrollment in the fourth quarter of 2026 and states it is capitalized to fund the study and operations through the third quarter of 2027.
Turn Therapeutics Inc. furnished an updated investor presentation outlining its dermatology pipeline, lead asset GX-03 and financial position. The company describes GX-03 as a non-systemic immunomodulation therapy targeting IL-36 and IL-31 for moderate to severe atopic dermatitis, supported by interim Phase 2 data showing meaningful reductions in EASI scores versus vehicle and a favorable safety profile.
The presentation also highlights Phase 3–ready data for onychomycosis, where GX-03 showed nail penetration and fungal burden reduction, and broader opportunities using its PermaFusion delivery platform. Financially, Turn reports $11M in cash as of March 31, 2026, total funding of $29M since 2015, expected Phase 3 R&D spend of $55–60M across two indications, and cash runway into Q1 2027.
Turn Therapeutics reported interim results from the first 50 subjects in its randomized, double-blind, vehicle-controlled Phase 2 trial of topical GX-03 for moderate-to-severe atopic dermatitis. In this interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity at 4 weeks (EASI-50), compared with 65.2% for vehicle.
Deeper response thresholds also favored GX-03, with Week 4 EASI-90 responses of 44.4% versus 30.4% for vehicle, rising by Week 8 to 51.9% versus 34.8%. No treatment-related serious adverse events, tolerability issues, or discontinuations were observed during the interim period, supporting a favorable safety and tolerability profile.
The company is using these findings to refine enrollment criteria, endpoint hierarchy, and overall trial optimization while enrollment continues, and plans FDA interactions to discuss regulatory strategy for GX-03. Turn Therapeutics expects to present more detailed data at the Jefferies Global Healthcare conference on June 4, 2026.
Turn Therapeutics filed a current report to share that a peer-reviewed article on its lead program, GX-03, has been published in the Journal of Dermatological Treatment. The study evaluated GX-03 in an IL-36–associated inflammatory model of Staphylococcus aureus–induced murine dermatitis and observed a clear clinical effect after seven days of twice-daily treatment.
The publication supports Turn’s strategy of targeting inflammation locally at the skin, focusing on cytokines such as IL-36. GX-03 is described as a first-in-class, non-systemic topical cytokine‑modulating therapy in development for moderate-to-severe atopic dermatitis and is currently in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.
Turn Therapeutics Inc. filed a current report to share that its CEO, Bradley Burnam, will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, from 9:55 AM to 10:25 AM EDT. A live webcast and a replay for about six months will be available on the company’s investor relations website. The company highlights its lead investigational therapy GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis targeting IL-36 and IL-31, which is in a Phase 2 randomized controlled trial with topline results expected in mid-2026.
Turn Therapeutics Inc. announced that it has appointed Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration, as its executive clinical and regulatory lead. He will oversee clinical and regulatory strategy for GX-03, the company’s investigational topical therapy for moderate-to-severe atopic dermatitis, which is currently in a Phase 2 randomized controlled trial with topline results expected in mid-2026.
GX-03 is described as a first-in-class, non-systemic, topical cytokine‑modulating therapy aimed at key inflammatory pathways in eczema and other inflammatory skin diseases. Turn Therapeutics positions itself as a biotechnology company focused on targeted, localized therapies for inflammatory diseases with high unmet medical need.
Turn Therapeutics Inc. reported financial results for the first quarter of 2026 and outlined key corporate developments. The company posted a net loss of $970,972, or $0.03 per share, compared with a net loss of $328,547, or $0.01 per share, a year earlier.
Cash and cash equivalents increased to $11.2 million as of March 31, 2026 from $5.1 million at year-end 2025, supported by an Avenue Capital Group growth capital facility of up to $25 million in term loans, including an initial funded tranche of $7 million. The lead drug candidate GX-03 continues in a Phase 2 trial for moderate-to-severe atopic dermatitis, with interim results expected in the second quarter of 2026 and topline data planned for mid-2026.
Turn Therapeutics Inc. reported full year 2025 results and provided clinical and corporate updates. Operating expenses rose to $5.9 million, driven mainly by general and administrative costs, leading to a net loss of $3.2 million compared with $1.8 million in 2024. Other income of $2.7 million, including gains from changes in fair value of a derivative liability instrument and a forward contract liability, partially offset operating losses. Cash and cash equivalents increased to $5.1 million and total assets to $12.2 million, with stockholders’ equity turning positive.
The company highlighted its Phase 2 trial of lead candidate GX-03 for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026. Turn also secured up to $25 million in growth capital from Avenue Capital Group, which it states is expected to extend its runway through the end of 2027, and referenced a global license, supply, and distribution agreement with Medline that it believes could enable revenue beginning in late 2026.
Turn Therapeutics Inc. entered into a growth capital loan agreement with Avenue Venture Opportunities Fund II for term loans of up to $25.0 million. An initial $7.0 million tranche is funded at closing, with up to $8.0 million in Tranche 2 and a discretionary Tranche 3 of up to $10.0 million tied to clinical and financing milestones and mutual agreement.
The loans bear interest at the greater of prime plus 5.50% or 12.25%, mature on October 1, 2029, and are secured by liens on all company assets, including intellectual property. Turn will make interest-only payments for at least 15 months, with potential extensions based on milestone achievement, followed by amortization to maturity.
As part of the deal, Turn paid a $150,000 commitment fee and agreed to a 3.75% final payment on aggregate funded amounts. The lender can convert up to $2.0 million of principal, rising to $3.0 million if Tranche 2 is funded, into common stock at 80% of the closing share price, and received an equity grant valued at $1.2 million. A participation right allows up to $1.0 million investment in future equity financings. A related press release states the financing is expected to extend Turn’s cash runway through its Phase 2 atopic dermatitis readout and potentially through the end of 2027.
Turn Therapeutics filed a current report to share a press release announcing that Robert Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, has been appointed Senior Advisor of Health Policy and Regulatory Affairs.
Dr. Redfield will advise on clinical development, public health considerations, and regulatory positioning of Turn’s lead investigational therapy, GX-03, which is in Phase 2 clinical trials. GX-03 is described as a first-in-class, non-systemic topical inhibitor in late-stage development for moderate-to-severe atopic dermatitis and other inflammatory dermatologic conditions.
Turn Therapeutics Inc. furnished a press release and updated investor presentation outlining upcoming appearances at the TD Cowen and Oppenheimer healthcare conferences and providing a detailed pipeline update. The company is developing GX-03, a first-in-class, non-systemic topical immunomodulator targeting IL-36, IL-31 and IL-4 for moderate-to-severe eczema, with a Phase 2 randomized controlled trial underway and topline results expected mid-2026.
The presentation highlights additional GX-03 opportunities in onychomycosis and psoriasis, plus a thermostable intranasal vaccine program enabled by the PermaFusion delivery platform. Turn reports raising about $21 million since 2015, cumulative cash burn of about $18 million, expected Phase 3 R&D spending of $55–60 million, and projected public-company G&A costs of about $250,000 per month. Existing device products are out-licensed to Medline and MiMedx with potential milestone payments exceeding $70 million.
Turn Therapeutics Inc. filed a current report to furnish a company press release under Item 7.01 (Regulation FD Disclosure). The report notes that the press release, dated January 12, 2026 and attached as Exhibit 99.1, is being treated as information that is "furnished" rather than "filed" for purposes of the Securities Exchange Act of 1934. This means it is not subject to the liability provisions of Section 18 unless the company later specifically incorporates it by reference into a Securities Act or Exchange Act filing.
Turn Therapeutics Inc. expanded its board of directors from five to six members and appointed Martin Dewhurst as an independent Class III director, effective January 7, 2026. He will serve until the 2028 annual stockholders’ meeting, unless he leaves earlier, and will chair the board’s compensation committee.
Dewhurst brings more than 30 years of global life sciences leadership, including senior advisory roles at GHO Capital, PJT Partners, and LightRock, and prior experience as a senior partner at McKinsey & Co. In connection with his appointment, he received restricted stock units with a grant-date fair value of $100,000 under the 2025 Omnibus Incentive Plan, vesting on the first anniversary of the grant or upon a change of control, whichever occurs first. After the first anniversary of the company’s direct listing effective date, he will be eligible for an annual RSU grant with a grant-date fair value of $70,000. The company also furnished a press release and an updated investor presentation dated January 7, 2026.